Endometriosis Pain Pipeline 2025: Therapies, MOA Insights, And Key Clinical Trial Updates By Delveinsight By Delveinsight Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, Abbvie/Neurocrine

(MENAFN- GetNews)

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Endometriosis Pain pipeline constitutes 5+ key companies continuously working towards developing 5+ Endometriosis Pain treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Endometriosis Pain Pipeline Insight, 2025 " report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Endometriosis Pain Market.

The Endometriosis Pain Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Endometriosis Pain Pipeline Report:

• Companies across the globe are diligently working toward developing novel Endometriosis Pain treatment therapies with a considerable amount of success over the years.

• Endometriosis Pain companies working in the treatment market are Organon, Ironwood Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, AbbVie/Neurocrine Biosciences, ObsEva/Kissei Pharmaceuticals, SWK/Enteris BioPharma, Bayer/Hope Medicine, Tiumbio, and others, are developing therapies for the Endometriosis Pain treatment

• Emerging Endometriosis Pain therapies in the different phases of clinical trials are- FOR 6219, IW-3300, MT-2990, ORIAHNN (elagolix/estradiol/norethindrone acetate), Linzagolix (OBE2109), OVAREST (leuprorelin oral), HMI-115, TU2670 (NCE-403), OG-6219, and others are expected to have a significant impact on the Endometriosis Pain market in the coming years.

• In July 2025, A drug candidate once described by Organon as its“biggest potential opportunity” failed in a Phase 2 clinical trial, leading the company to discontinue its development for endometriosis. Organon, a women's health-focused company, acquired the candidate OG-6219 through its $75 million acquisition of Forendo Pharma in 2021, shortly after spinning off from Merck & Co. The company launched a Phase 2 trial in 2022, enrolling 354 premenopausal women suffering from moderate to severe endometriosis-related pain. Participants were randomized to receive one of three doses of OG-6219 or a placebo. Organon had hoped the drug would alleviate pain by inhibiting a hormone involved in uterine tissue growth and inflammation, but the trial failed to meet expectations.

• In March 2025, The first long-term daily oral treatment for endometriosis has been recommended for routine use on the NHS in England. In its final draft guidance, the National Institute for Health and Care Excellence (NICE) advised that relugolix-estradiol-norethisterone, also known as relugolix combination therapy (relugolix CT), should be offered to adults of reproductive age whose endometriosis symptoms persist despite previous medical or surgical treatments. This marks the first time a daily pill of this kind has been approved for long-term endometriosis management by the NHS, with around 1,000 women expected to benefit each year.

• In October 2024, Lisata Therapeutics, Inc. entered into a sponsored research collaboration with the University of Cincinnati to explore its innovative cyclic peptide candidate, certepetide, in combination with bevacizumab (a VEGF inhibitor). The study will utilize a preclinical animal model to evaluate the potential of this combination therapy for treating endometriosis.

• In October 2024, Hope Medicine Inc. reported positive findings from an interim analysis of its global Phase II trial, titled "A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of HMI-115 in Women with Moderate to Severe Endometriosis-Associated Pain Over a 12-Week Treatment Period." HMI-115, a monoclonal antibody that inhibits the prolactin receptor, represents a first-in-class therapy for endometriosis. Notably, the National Medical Products Administration (NMPA) in China has granted HMI-115 Breakthrough Therapy Designation.

• In May 2024, Neurocrine Biosciences, Inc. has commenced its Phase I first-in-human clinical trial to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of the investigational drug NBI-1117567 in healthy adults. NBI-1117567 is an experimental oral selective muscarinic agonist, with a preference for M1 over M4 receptors, being developed as a potential treatment for neurological and neuropsychiatric disorders

• In May 2024, TiumBio Co., Ltd., a company dedicated to developing innovative treatments for rare and incurable diseases, reported positive topline results from its Phase 2a clinical trial evaluating Merigolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, for the treatment of moderate to severe endometriosis-associated pain.

• In April 2024, By the end of this year, Gynica, an Israeli company, plans to administer the first dose in a Phase I trial for its cannabinoid-based therapies, IntraVagS301 and IntraVagS302, designed for endometriosis. This trial aims to assess the safety, toxicity, and pharmacokinetics of these drugs, which utilize microencapsulation technology

Endometriosis Pain Overview

Endometriosis pain refers to the discomfort, cramping, and other symptoms experienced by individuals with endometriosis, a condition where tissue similar to the lining of the uterus grows outside the uterus. The pain associated with endometriosis can vary widely in intensity and may occur before, during, or after menstruation. It can also manifest as chronic pelvic pain, lower back pain, painful intercourse, and pain during bowel movements or urination.

Get a Free Sample PDF Report to know more about Endometriosis Pain Pipeline Therapeutic Assessment-

Emerging Endometriosis Pain Drugs Under Different Phases of Clinical Development Include:

• FOR 6219: Organon

• IW-3300: Ironwood Pharmaceuticals

• MT-2990: Mitsubishi Tanabe Pharma Corporation

• ORIAHNN (elagolix/estradiol/norethindrone acetate): AbbVie/Neurocrine Biosciences

• Linzagolix (OBE2109): ObsEva/Kissei Pharmaceuticals

• OVAREST (leuprorelin oral): SWK/Enteris BioPharma

• HMI-115: Bayer/Hope Medicine

• TU2670 (NCE-403): Tiumbio

• OG-6219: Organon

• Quinagolide: Ferring Pharmaceuticals

• Linzagolix: ObsEva

Endometriosis Pain Route of Administration

Endometriosis Pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Inhalation

• Inhalation/Intravenous/Oral

• Intranasal

• Intravenous

• Intravenous/ Subcutaneous

• NA

• Oral

• Oral/intranasal/subcutaneous

• Parenteral

• Subcutaneous

Endometriosis Pain Molecule Type

Endometriosis Pain Products have been categorized under various Molecule types, such as

• Antibody

• Antisense oligonucleotides

• Immunotherapy

• Monoclonal antibody

• Peptides

• Protein

• Recombinant protein

• Small molecule

• Stem Cell

• Vaccine

Endometriosis Pain Pipeline Therapeutics Assessment

• Endometriosis Pain Assessment by Product Type

• Endometriosis Pain By Stage and Product Type

• Endometriosis Pain Assessment by Route of Administration

• Endometriosis Pain By Stage and Route of Administration

• Endometriosis Pain Assessment by Molecule Type

• Endometriosis Pain by Stage and Molecule Type

DelveInsight's Endometriosis Pain Report covers around 5+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Endometriosis Pain product details are provided in the report. Download the Endometriosis Pain pipeline report to learn more about the emerging Endometriosis Pain therapies

Some of the key companies in the Endometriosis Pain Therapeutics Market include:

Key companies developing therapies for Endometriosis Pain are - AbbVie, Neurocrine Biosciences, Kissei Pharmaceuticals, SWK, Enteris BioPharma, Bayer, Hope Medicine, Tiumbio, Organon, Ferring Pharmaceuticals, ObsEva SA, Myovant Sciences, Hope Medicine (Nanjing) Co., Ltd, TiumBio Co., Ltd., Mitsubishi Tanabe Pharma, and others.

Endometriosis Pain Pipeline Analysis:

The Endometriosis Pain pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Endometriosis Pain with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Endometriosis Pain Treatment.

• Endometriosis Pain key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Endometriosis Pain Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Endometriosis Pain market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Endometriosis Pain drugs and therapies

Endometriosis Pain Pipeline Market Drivers

• The development of drug delivery systems represents a new approach in pain treatment among endometriosis patients, extensive research on Non-steroidal anti-inflammatory drugs are some of the important factors that are fueling the Endometriosis Pain Market.

Endometriosis Pain Pipeline Market Barriers

• However, less robust pipeline, high cost of treatment procedures and other factors are creating obstacles in the Endometriosis Pain Market growth.

Scope of Endometriosis Pain Pipeline Drug Insight

• Coverage: Global

• Key Endometriosis Pain Companies: Organon, Ironwood Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, AbbVie/Neurocrine Biosciences, ObsEva/Kissei Pharmaceuticals, SWK/Enteris BioPharma, Bayer/Hope Medicine, Tiumbio, and others

• Key Endometriosis Pain Therapies: FOR 6219, IW-3300, MT-2990, ORIAHNN (elagolix/estradiol/norethindrone acetate), Linzagolix (OBE2109), OVAREST (leuprorelin oral), HMI-115, TU2670 (NCE-403), OG-6219, and others

• Endometriosis Pain Therapeutic Assessment: Endometriosis Pain current marketed and Endometriosis Pain emerging therapies

• Endometriosis Pain Market Dynamics: Endometriosis Pain market drivers and Endometriosis Pain market barriers

Request for Sample PDF Report for Endometriosis Pain Pipeline Assessment and clinical trials

Table of Contents

1. Endometriosis Pain Report Introduction

2. Endometriosis Pain Executive Summary

3. Endometriosis Pain Overview

4. Endometriosis Pain- Analytical Perspective In-depth Commercial Assessment

5. Endometriosis Pain Pipeline Therapeutics

6. Endometriosis Pain Late Stage Products (Phase II/III)

7. Endometriosis Pain Mid Stage Products (Phase II)

8. Endometriosis Pain Early Stage Products (Phase I)

9. Endometriosis Pain Preclinical Stage Products

10. Endometriosis Pain Therapeutics Assessment

11. Endometriosis Pain Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Endometriosis Pain Key Companies

14. Endometriosis Pain Key Products

15. Endometriosis Pain Unmet Needs

16 . Endometriosis Pain Market Drivers and Barriers

17. Endometriosis Pain Future Perspectives and Conclusion

18. Endometriosis Pain Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

MENAFN03092025003238003268ID1110013897